BibTex RIS Kaynak Göster

-

Yıl 2013, Cilt: 26 Sayı: 2, 90 - 93, 01.10.2015

Fatma Sarı Doğan Arzu Denizbaşı Altınok Özge Ecmel Onur Özlem Güneysel Haldun Akoğlu

https://doi.org/10.5472/MMJ.2013.02515.1
Cited By: 2

Öz

Objectives: Various levels of dysfunction and damage can occur in the central nervous system of patients experiencing seizures. It is known that these impairments can be assessed by measurement of biochemical markers. S100B proteins have been extensively studied in recent years. We have assessed whether there is a change in serum S100B protein levels during seizures which lead to cerebral hypoperfusion and/or hypoxia.Patients and Methods: A total of 56 patients admitted to an emergency service due to seizures and more than 18 years of age were included in the study. The control group consisted of 20 patients who were admitted to the emergency service due to complaints other than seizures. Results: There was a significant difference between the groups in terms of gender, hemoglobin levels and S100B levels, whereas there was no significant difference in terms of glucose, sodium and potassium levels. The S100B levels were significantly lower in the patient group compared to the control group. Hemoglobin levels was significantly lower in the control group compared to the patient group.Conclusion: Serum S100B protein concentration was found to be significantly lower in patients compared to controls

Anahtar Kelimeler

Seizure S100B protein Emergency

Kaynakça

  • 1. Engel J Jr. International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42:796-803.x doi: 10.1046/j.1528-1157.2001.10401.x
  • 2. ACEP Clinical Policies Committee. Clinical Policies Subcommittee on Seizures. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med 2004; 43:605-25.doi:10.1016/j. annemergmed.2004.01.017
  • 3. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60:540-51. doi: 10.1002/jemt.10296.
  • 4. Rothermundt M, Peters M, Prehn JH, et al. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003; 60:614-32. doi: 10.1002/ jemt.10303
  • 5. Donato R, Sorci G, Riuzzi F, et al.S100B’ s double life: Intracellular regulator and extracellular signal. Biochim Biophys Acta 2009;1008- 22. doi: 10.1016/j.bbamcr.2008.11.009.
  • 6. Adami C, Sorci G, Blasi E, et al. S100B expression in and effects on microglia. Glia 2001; 33:131-42. .doi:10.1002/1098- 1136(200102)33:2<131::AID-GLIA1012>3.3.CO;2-4
  • 7. Pinto SS, Gottfried C, Mendez A, et al. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett 2000; 486:203-7. doi:10.1016/S0014- 5793(00)02301-2
  • 8. Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006; 23:1185-200. doi:10.1089/neu.2006.23.1185
  • 9. Delgado P, Alvarez Sabin J, Santamarina E, et al. Plasma S100B level after acute spontaneous intracerebral hemorrhage. Stroke 2006; 37:2837-9. doi:10.1161/01.STR.0000245085.58807.ad
  • 10. Wunderlich MT, Ebert AD, Kratz T, et al. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999; 30:1190-5. doi: 10.1161/01. STR.30.6.1190
  • 11. Sakatani S, Seto-Ohshima A, Shinohara Y, et al. Neural-activitydependent release of S100B from astrocytes enhances kainate-induces gamma oscillations in vivo. 2008; 22:28:10928-36. doi:10.1523/ JNEUROSCI.3693-08.2008
  • 12. Oses JP, Leke R, Portela LV, et al. Biochemical brain markers and purinergic parameters in rat CSF after seizure induced by pentylenetetrazol. Brain Res Bull 2004; 64:237-42. doi: 10.1016/j. brainresbull.2004.07.006
  • 13. Otto M, Wiltfang J, Mogge S,and et al. Changing levels of S100 protein in serum after epileptic seizures. Epilepsia 1998; (suppl)39:73
  • 14. Palmio J, Peltola J, Vuorinen P, et al. Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent noncomplicated tonic-clonic seizures. J Neurol Sci 2001; 183:27-31. doi:10.1016/S0022-510X(00)00478.0
  • 15. Büttner T, Lack B, Jäger M, et al. Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures. J Neurol 1999; 246:459-61.
  • 16. Leutmezer F, Wagner O, Baumgartner C. Serum s-100 protein is not a suitable seizure marker in temporal lobe epilepsy. Epilepsia 2002; 43:1172-4. doi: 10.1046/j.1528-1157.2002.50101.x
  • 17. Palmio J, Keranen T, Alapirtti T, et al. Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: a video-EEG study. Epilepsy Res 2008; 81:155-60.
  • 18. Calik M, Abuhandan M, Sönmezler, et al. Elevated serum S100B levels in children with temporal lobe epilepy. Seizure 2013; 22: 99- 102. doi: 10.1016/ j.seizure.2012.10.012
  • 19. Atıcı Y, Alehan F, Sezer T, et al. Serum s100B levels in children with simple febrile seizures. Seizure 2012; 21: 175-7. doi: 10.1016/j. seizure.2011.11.003.
  • 20. Mikkonen K, Pekkala N, Pokka T, et al. S100B proteins in febrile seizures. Seizure. 2012; 21: 144-6. doi:10.1016/j.seizure.2011.10.006.
  • 21. Dyck RH, Bogoch II, Marks A, et al.Enhanced epileptogenesis in S100B knockout mice. Brain Res Mol Brain Res 2002; 106:22-9. doi: 10.1016/S0169-328X(02)00406-0.
  • 22. Portela LV, Tort AB, Schaf DV, et al. The serum S100B concentration is age dependent. Clin Chem 2002; 48:950-2.
  • 23. Bharucha NE, Bharucha EP, Bharucha AE, et al. Prevalence of epilepsy in the Parsi community of Bombay. Epilepsia 1988; 29:111-5. doi:10.1111/j.1528-1157.1988.tb04405.x

Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi

Yıl 2013, Cilt: 26 Sayı: 2, 90 - 93, 01.10.2015

Fatma Sarı Doğan Arzu Denizbaşı Altınok Özge Ecmel Onur Özlem Güneysel Haldun Akoğlu

https://doi.org/10.5472/MMJ.2013.02515.1
Cited By: 2

Öz

Amaç: Nöbet geçiren hastalarda santral sinir sisteminde farklı düzeylerde disfonksiyon ve hasar oluşabilmektedir. Bu hasarlanmaların biyokimyasal belirteçlere bakılmak suretiyle değerlendirilebileceği bilinmektedir. Son yıllarda giderek artan bir şekilde “beyine özel göstergeler” araştırılmaktadır. Bu çalışmada serebral hipoperfüzyon ve/veya hipoksiye neden olan nöbet durumlarında serum S100B protein düzeylerinde değişiklik oluşup oluşmadığının belirlenmesi amaçlanmıştır. Hastalar ve Yöntem: Acil servise nöbet şikayetiyle başvuran ≥18 yaşında 56 hasta çalışmaya alınmıştır. Kontrol grubunu nöbet dışı bir şikayetle acil servise başvuran 20 hasta oluşturmuştur. Bulgular: Gruplar arasında cinsiyet, hemoglobin değerleri ve S100B proteini açısından anlamlı olarak fark bulunmuştur. Bunun yanında glukoz, sodyum ve potasyum değerleri açısından gruplar arasında anlamlı olarak bir fark yoktur. Hasta grubu S100B değerleri, kontrol grubuna göre istatistiksel açıdan anlamlı olarak düşük bulunmuştur. Hemoglobin değerleri ise, kontrol grubunda, hasta grubuna göre anlamlı olarak düşük bulunmuştur. Sonuç: Hasta grubu serum S100B protein konsantrasyonu, kontrol grubundan anlamlı olarak düşük bulunmuştur.

Anahtar Kelimeler

Nöbet S100B protein Acil

Kaynakça

  • 1. Engel J Jr. International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42:796-803.x doi: 10.1046/j.1528-1157.2001.10401.x
  • 2. ACEP Clinical Policies Committee. Clinical Policies Subcommittee on Seizures. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med 2004; 43:605-25.doi:10.1016/j. annemergmed.2004.01.017
  • 3. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60:540-51. doi: 10.1002/jemt.10296.
  • 4. Rothermundt M, Peters M, Prehn JH, et al. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003; 60:614-32. doi: 10.1002/ jemt.10303
  • 5. Donato R, Sorci G, Riuzzi F, et al.S100B’ s double life: Intracellular regulator and extracellular signal. Biochim Biophys Acta 2009;1008- 22. doi: 10.1016/j.bbamcr.2008.11.009.
  • 6. Adami C, Sorci G, Blasi E, et al. S100B expression in and effects on microglia. Glia 2001; 33:131-42. .doi:10.1002/1098- 1136(200102)33:2<131::AID-GLIA1012>3.3.CO;2-4
  • 7. Pinto SS, Gottfried C, Mendez A, et al. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett 2000; 486:203-7. doi:10.1016/S0014- 5793(00)02301-2
  • 8. Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006; 23:1185-200. doi:10.1089/neu.2006.23.1185
  • 9. Delgado P, Alvarez Sabin J, Santamarina E, et al. Plasma S100B level after acute spontaneous intracerebral hemorrhage. Stroke 2006; 37:2837-9. doi:10.1161/01.STR.0000245085.58807.ad
  • 10. Wunderlich MT, Ebert AD, Kratz T, et al. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999; 30:1190-5. doi: 10.1161/01. STR.30.6.1190
  • 11. Sakatani S, Seto-Ohshima A, Shinohara Y, et al. Neural-activitydependent release of S100B from astrocytes enhances kainate-induces gamma oscillations in vivo. 2008; 22:28:10928-36. doi:10.1523/ JNEUROSCI.3693-08.2008
  • 12. Oses JP, Leke R, Portela LV, et al. Biochemical brain markers and purinergic parameters in rat CSF after seizure induced by pentylenetetrazol. Brain Res Bull 2004; 64:237-42. doi: 10.1016/j. brainresbull.2004.07.006
  • 13. Otto M, Wiltfang J, Mogge S,and et al. Changing levels of S100 protein in serum after epileptic seizures. Epilepsia 1998; (suppl)39:73
  • 14. Palmio J, Peltola J, Vuorinen P, et al. Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent noncomplicated tonic-clonic seizures. J Neurol Sci 2001; 183:27-31. doi:10.1016/S0022-510X(00)00478.0
  • 15. Büttner T, Lack B, Jäger M, et al. Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures. J Neurol 1999; 246:459-61.
  • 16. Leutmezer F, Wagner O, Baumgartner C. Serum s-100 protein is not a suitable seizure marker in temporal lobe epilepsy. Epilepsia 2002; 43:1172-4. doi: 10.1046/j.1528-1157.2002.50101.x
  • 17. Palmio J, Keranen T, Alapirtti T, et al. Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: a video-EEG study. Epilepsy Res 2008; 81:155-60.
  • 18. Calik M, Abuhandan M, Sönmezler, et al. Elevated serum S100B levels in children with temporal lobe epilepy. Seizure 2013; 22: 99- 102. doi: 10.1016/ j.seizure.2012.10.012
  • 19. Atıcı Y, Alehan F, Sezer T, et al. Serum s100B levels in children with simple febrile seizures. Seizure 2012; 21: 175-7. doi: 10.1016/j. seizure.2011.11.003.
  • 20. Mikkonen K, Pekkala N, Pokka T, et al. S100B proteins in febrile seizures. Seizure. 2012; 21: 144-6. doi:10.1016/j.seizure.2011.10.006.
  • 21. Dyck RH, Bogoch II, Marks A, et al.Enhanced epileptogenesis in S100B knockout mice. Brain Res Mol Brain Res 2002; 106:22-9. doi: 10.1016/S0169-328X(02)00406-0.
  • 22. Portela LV, Tort AB, Schaf DV, et al. The serum S100B concentration is age dependent. Clin Chem 2002; 48:950-2.
  • 23. Bharucha NE, Bharucha EP, Bharucha AE, et al. Prevalence of epilepsy in the Parsi community of Bombay. Epilepsia 1988; 29:111-5. doi:10.1111/j.1528-1157.1988.tb04405.x
Toplam 23 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Fatma Sarı Doğan Bu kişi benim

Arzu Denizbaşı Altınok Bu kişi benim

Özge Ecmel Onur Bu kişi benim

Özlem Güneysel Bu kişi benim

Haldun Akoğlu Bu kişi benim

Yayımlanma Tarihi 1 Ekim 2015
Yayımlandığı Sayı Yıl 2013 Cilt: 26 Sayı: 2

Kaynak Göster

APA Sarı Doğan, F., Denizbaşı Altınok, A., Ecmel Onur, Ö., Güneysel, Ö., vd. (2015). Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi. Marmara Medical Journal, 26(2), 90-93. https://doi.org/10.5472/MMJ.2013.02515.1
AMA Sarı Doğan F, Denizbaşı Altınok A, Ecmel Onur Ö, Güneysel Ö, Akoğlu H. Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi. Marmara Med J. Ekim 2015;26(2):90-93. doi:10.5472/MMJ.2013.02515.1
Chicago Sarı Doğan, Fatma, Arzu Denizbaşı Altınok, Özge Ecmel Onur, Özlem Güneysel, ve Haldun Akoğlu. “Acil Servise nöbet şikayeti Ile başvuran Hastalarda S100B Protein düzeyi”. Marmara Medical Journal 26, sy. 2 (Ekim 2015): 90-93. https://doi.org/10.5472/MMJ.2013.02515.1.
EndNote Sarı Doğan F, Denizbaşı Altınok A, Ecmel Onur Ö, Güneysel Ö, Akoğlu H (01 Ekim 2015) Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi. Marmara Medical Journal 26 2 90–93.
IEEE F. Sarı Doğan, A. Denizbaşı Altınok, Ö. Ecmel Onur, Ö. Güneysel, ve H. Akoğlu, “Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi”, Marmara Med J, c. 26, sy. 2, ss. 90–93, 2015, doi: 10.5472/MMJ.2013.02515.1.
ISNAD Sarı Doğan, Fatma vd. “Acil Servise nöbet şikayeti Ile başvuran Hastalarda S100B Protein düzeyi”. Marmara Medical Journal 26/2 (Ekim 2015), 90-93. https://doi.org/10.5472/MMJ.2013.02515.1.
JAMA Sarı Doğan F, Denizbaşı Altınok A, Ecmel Onur Ö, Güneysel Ö, Akoğlu H. Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi. Marmara Med J. 2015;26:90–93.
MLA Sarı Doğan, Fatma vd. “Acil Servise nöbet şikayeti Ile başvuran Hastalarda S100B Protein düzeyi”. Marmara Medical Journal, c. 26, sy. 2, 2015, ss. 90-93, doi:10.5472/MMJ.2013.02515.1.
Vancouver Sarı Doğan F, Denizbaşı Altınok A, Ecmel Onur Ö, Güneysel Ö, Akoğlu H. Acil servise nöbet şikayeti ile başvuran hastalarda S100B protein düzeyi. Marmara Med J. 2015;26(2):90-3.

Cited By

The S100B Protein in Epilepsy
Archives Of Epilepsy
https://doi.org/10.4274/ArchEpilepsy.2023.231289
Elevated Blood-Based Brain Biomarker Levels in Patients with Epileptic Seizures: A Systematic Review and Meta-analysis
ACS Chemical Neuroscience
Leila Simani
https://doi.org/10.1021/acschemneuro.0c00492